WuXi STA

API-Oligo

API-Oligo

Our oligonucleotide API process development and manufacturing platform provides one-stop solution from preclinical to commercial from one site in Changzhou, China.  We have built industry-leading capability and capacity to support your needs across all development stages, with knowledge retention through the product life cycle.  In addition, Changzhou site is within 1-hour drive from DP site in Wuxi city, enabling faster, simpler and more cost effective oligo CMC development for both API and drug product

Process Development

A highly experienced oligo R&D team with a few hundreds of scientists with 100+ projects completed

• Cover molecule types of ASO, siRNA, Aptamer, Oligo conjugates, PMO and PPMO
• Utilize various modified monomers (2'-H, 2'-OH, 2'-F, 2'-OMe, 2'-OMOE, LNA, cEt, LNA, Vinyl-phosphate, Spacer,…)
• Chiral oligo synthesis
• Modification at 3'-end or 5'-end with GalNAc, triphosphate, cholesterol, saccharides, peptides, maleimide… 

Manufacturing Capacity

With our global standard quality system, we are uniquely positioned to be your strategic manufacturing partner for reliable, cost effective and long-term supplies of your oligonucleotide APIs from mmol to mol. Our unique "one-site" platform ensures knowledge retention and seamless scale up throughout your product life cycle, and expediates your development by eliminating the trouble of multi companies/sites transfer.

Capacity Expansion Plan

Currently we have 4 middle-scale lines, 6 large-scale lines with 6 mol total capacity per synthesis run. By 2023, we will add more middle-scale line and large-scale lines with ~10 mol total capacity per synthesis run.